-
Something wrong with this record ?
Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia
F. Baron, M. Labopin, J. Tischer, F. Ciceri, AM. Raiola, D. Blaise, S. Sica, J. Vydra, R. Fanin, JL. Diez-Martin, CE. Bulabois, F. Stölzel, A. Busca, P. Jindra, Y. Koc, P. Chevallier, E. Forcade, W. Rösler, J. Passweg, A. Kulagin, AM. Carella, C....
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1997 to 1 year ago
Freely Accessible Science Journals
from 1997 to 1 year ago
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
- MeSH
- Leukemia, Myeloid, Acute * drug therapy MeSH
- Cyclophosphamide therapeutic use MeSH
- Adult MeSH
- Transplantation, Haploidentical adverse effects MeSH
- Humans MeSH
- Graft vs Host Disease * etiology MeSH
- Unrelated Donors MeSH
- Transplantation Conditioning methods MeSH
- Retrospective Studies MeSH
- Hematopoietic Stem Cell Transplantation * methods MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) is frequently used as treatment for patients with active acute myeloid leukemia (AML). Here, we investigated whether 9/10 HLA-mismatched unrelated donor transplantation (MMUD-HCT) with post-transplant cyclophosphamide (PTCy) is an adequate alternative. Inclusion criteria in this retrospective registry study consisted of adult patients, first HCT with a Haplo donor or MMUD between 2010 and 2020 using PTCy as graft-versus-host disease (GVHD) prophylaxis, and primary refractory or relapsed disease. MMUD patients were pair-matched 1 to 2 with Haplo-recipients. A total of 73 MMUD patients met the inclusion criteria. Their data were compared to those of 146 Haplo patients in a matched-pair analysis. Median follow-up was 27 months in MMUD patients and 36 months in Haplo recipients. Two-year incidences of relapse and non-relapse mortality (NRM) were 40% and 18% in MMUD patients, respectively, versus 50% (P = 0.23) and 24% (P = 0.18) in Haplo recipients. Two-year leukemia-free survival (LFS) and overall survival (OS) was 42% and 46% in MMUD recipients, respectively, versus 26% (P = 0.1) and 28% (P = 0.061) in Haplo-patients. In conclusions, in AML patients with active disease at transplantation, MMUD-HCT results in at least comparable outcomes to Haplo-HCT when PTCy is applied.
CHU Grenoble Alpes Université Grenoble Alpes Service d'Hématologie CS 10217 Grenoble France
CHU Nantes Department D'Hematologie Nantes France
Department of Hematology Oncology Charles University Hospital Pilsen Czech Republic
Department of Internal Medicine 5 University Hospital Erlangen Erlangen Germany
Department of Internal Medicine American University of Beirut Medical Center Beirut Lebanon
Division of Hematology University Hospital and DAME Udine Italy
EBMT Paris Study Office CEREST TC Paris France
Hematology ICANS University Hospital Strasbourg France
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS Ospedale San Raffaele University Vita Salute San Raffaele Milan Italy
Laboratory of Hematology GIGA I3 University of Liege and CHU of Liège Liege Belgium
Medicana International Hospital Istanbul Bone Marrow Transplant Unit Istanbul Turkey
Ospedale San Gerardo Clinica Ematologica dell'Universita Milano Biocca Monza Italy
Ospedale San Martino Department of Haematology 2 Genova Italy
RM Gorbacheva Research Institute Pavlov University St Petersburg Russia
Service d'Hématologie Clinique et Thérapie Cellulaire CHU Bordeaux F 33000 Bordeaux France
Service d'Hématologie Clinique Hôpital Saint Antoine AP HP Paris France
Sorbonne University Paris France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032884
- 003
- CZ-PrNML
- 005
- 20240528145530.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-022-01781-9 $2 doi
- 035 __
- $a (PubMed)35978005
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Baron, Frédéric $u Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium. f.baron@ulg.ac.be $1 https://orcid.org/0000000229443812
- 245 10
- $a Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia / $c F. Baron, M. Labopin, J. Tischer, F. Ciceri, AM. Raiola, D. Blaise, S. Sica, J. Vydra, R. Fanin, JL. Diez-Martin, CE. Bulabois, F. Stölzel, A. Busca, P. Jindra, Y. Koc, P. Chevallier, E. Forcade, W. Rösler, J. Passweg, A. Kulagin, AM. Carella, C. Simand, A. Bazarbachi, P. Pioltelli, A. Nagler, M. Mohty
- 520 9_
- $a HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) is frequently used as treatment for patients with active acute myeloid leukemia (AML). Here, we investigated whether 9/10 HLA-mismatched unrelated donor transplantation (MMUD-HCT) with post-transplant cyclophosphamide (PTCy) is an adequate alternative. Inclusion criteria in this retrospective registry study consisted of adult patients, first HCT with a Haplo donor or MMUD between 2010 and 2020 using PTCy as graft-versus-host disease (GVHD) prophylaxis, and primary refractory or relapsed disease. MMUD patients were pair-matched 1 to 2 with Haplo-recipients. A total of 73 MMUD patients met the inclusion criteria. Their data were compared to those of 146 Haplo patients in a matched-pair analysis. Median follow-up was 27 months in MMUD patients and 36 months in Haplo recipients. Two-year incidences of relapse and non-relapse mortality (NRM) were 40% and 18% in MMUD patients, respectively, versus 50% (P = 0.23) and 24% (P = 0.18) in Haplo recipients. Two-year leukemia-free survival (LFS) and overall survival (OS) was 42% and 46% in MMUD recipients, respectively, versus 26% (P = 0.1) and 28% (P = 0.061) in Haplo-patients. In conclusions, in AML patients with active disease at transplantation, MMUD-HCT results in at least comparable outcomes to Haplo-HCT when PTCy is applied.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a haploidentická transplantace $x škodlivé účinky $7 D000075442
- 650 _2
- $a nepříbuzný dárce $7 D061349
- 650 _2
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 12
- $a nemoc štěpu proti hostiteli $x etiologie $7 D006086
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 12
- $a akutní myeloidní leukemie $x farmakoterapie $7 D015470
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Labopin, Myriam $u EBMT Paris Study Office/CEREST-TC, Paris, France $u Service d'Hématologie Clinique, Hôpital Saint-Antoine, AP-HP, Paris, France $u INSERM UMRs 938, Paris, France $u Sorbonne University, Paris, France $1 https://orcid.org/0000000345144748
- 700 1_
- $a Tischer, Johanna $u University Hospital of Munich - Campus Grosshadern, LMU, Department of Internal Medicine III, München, Germany
- 700 1_
- $a Ciceri, Fabio $u IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy $1 https://orcid.org/0000000308730123
- 700 1_
- $a Raiola, Anna Maria $u Ospedale San Martino, Department of Haematology II, Genova, Italy
- 700 1_
- $a Blaise, Didier $u Programme de Transplantation &Therapie Cellulaire, Département d'hématologie Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Institut Paoli Calmettes, Marseille, France $1 https://orcid.org/0000000256849447
- 700 1_
- $a Sica, Simona $u Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy $u Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy
- 700 1_
- $a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
- 700 1_
- $a Fanin, Renato $u Division of Hematology, University Hospital and DAME, Udine, Italy
- 700 1_
- $a Diez-Martin, Jose Luis $u Head of Hematology Department, Hospital G U Gregorio Marañon, Instituto de Investigación Sanitaria Gregorio Marañon, Medicine Dpt. UCM, Madrid, Spain
- 700 1_
- $a Bulabois, Claude Eric $u CHU Grenoble Alpes - Université Grenoble Alpes, Service d'Hématologie, CS, 10217, Grenoble, France
- 700 1_
- $a Stölzel, Friedrich $u Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany $1 https://orcid.org/0000000306535332
- 700 1_
- $a Busca, Alessandro $u S.S.C.V.D Trapianto di Cellule Staminali A.O.U Citta della Salute e della Scienza di Torino, Torino, Italy $1 https://orcid.org/0000000153615613
- 700 1_
- $a Jindra, Pavel $u Department of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic $1 https://orcid.org/0000000284157069
- 700 1_
- $a Koc, Yener $u Medicana International Hospital Istanbul, Bone Marrow Transplant Unit, Istanbul, Turkey
- 700 1_
- $a Chevallier, Patrice $u CHU Nantes, Department D'Hematologie, Nantes, France
- 700 1_
- $a Forcade, Edouard $u Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, F-33000, Bordeaux, France $1 https://orcid.org/0000000288732868
- 700 1_
- $a Rösler, Wolf $u Department of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany
- 700 1_
- $a Passweg, Jakob $u University Hospital Hematology, Basel, Switzerland
- 700 1_
- $a Kulagin, Alexander $u RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia $1 https://orcid.org/0000000295894136
- 700 1_
- $a Carella, Angelo Michele $u Ematologia e Centro Trapianti CSE Dipartimento di Scienze Mediche Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
- 700 1_
- $a Simand, Celestine $u Hematology, ICANS, University Hospital, Strasbourg, France
- 700 1_
- $a Bazarbachi, Ali $u Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon $1 https://orcid.org/0000000271714997
- 700 1_
- $a Pioltelli, Pietro $u Ospedale San Gerardo, Clinica Ematologica dell'Universita Milano-Biocca, Monza, Italy
- 700 1_
- $a Nagler, Arnon $u Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel $1 https://orcid.org/0000000207631265
- 700 1_
- $a Mohty, Mohamad $u EBMT Paris Study Office/CEREST-TC, Paris, France $u Service d'Hématologie Clinique, Hôpital Saint-Antoine, AP-HP, Paris, France $u INSERM UMRs 938, Paris, France $u Sorbonne University, Paris, France $1 https://orcid.org/000000027264808X $7 xx0317729
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 57, č. 11 (2022), s. 1657-1663
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35978005 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20240528145526 $b ABA008
- 999 __
- $a ok $b bmc $g 1891563 $s 1184219
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 57 $c 11 $d 1657-1663 $e 20220817 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20230120
